**Supplementary Table 1. Interim analysis of Grade ≥3 hematologic toxicity in the first 10 patients recruited to the combination arm (radium-223 + enzalutamide).**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Proportion of Subjects with Grade ≥3 Toxicity** | |  |
|  | **Null Hypothesis**  **(Parker et al. (2013) [1])** | **Combination Arm\*\***  **(This study)** | **P-value\*\*\*** |
| **Hematologic AEs** | 12.7%\* | 20% (2/10) | 0.37 |
| **Neutropenia** | 2.2% | 10% (1/10) | 0.20 |
| **Anemia** | 12.7% | 0% (0/10) | 1.00 |
| **Thrombocytopenia** | 6.5% | 10% (1/10) | 0.49 |

\* 12.7% is a lower bound for the proportion of subjects with any grade ≥3 hematologic toxicity in the ALSYMPCA trial [1]. \*\* Combination Arm = radium-223 + enzalutamide (first 10 patients recruited). \*\*\* One sided exact binomial test with significance at 0.05.

**References**

1. Parker, C., Nilsson, S., Heinrich, D., et al., *Alpha emitter radium-223 and survival in metastatic prostate cancer.* N Engl J Med, 2013. **369**(3): p. 213-23.